Investigation of a Novel Silicone Dressing to Maximize the Outcomes of Scar Revision Procedures (IMPROVE): Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Investigation of a Novel Silicone Dressing to Maximize the Outcomes of Scar Revision Procedures (IMPROVE) (NCT01430130), a na na study. The primary outcome is Visual Analogue Scale (VAS).

2. Clinical Question

The study is framed around whether an investigational dressing can minimize scar formation after a scar-revision procedure. Its design uses two portions of the same revised incision, rather than two separately randomized participant groups. This makes the intended comparison a within-participant comparison of treated and control sides. However, the registry record does not report how the side or location receiving the device was assigned, whether the assessor was blinded to treatment, or what statistical method was used to compare the portions.

The primary endpoint is the Visual Analogue Scale (VAS) Scar Score at 6 months. The described scale represents scar quality, from normal skin at 0 to a poor scar at 10. The registry record identifies an independent panel as the assessor for the primary outcome. Although that description clarifies what was intended to be measured, it does not give the observed scores, the number of participants with scores, or an estimate of the treated-versus-control contrast. The clinical question can therefore be stated from the registered design, but the record does not provide the result needed to quantify the comparison.

3. Trial Design

IMPROVE is identified as a completed study with enrollment of 12. The registry lists the phase and allocation as NA, masking as none, and the model as single group. The intervention is the embrace device, classified as a device. The record describes treatment of half of each revised incision with the device and treatment of the other half according to the investigator’s standard of care. Participants served as their own controls.

This arrangement differs from a parallel-group randomized trial. The comparison is between portions of an incision within the same participant, not between independently assigned participant groups. The registry record itself flags that allocation is not randomized and that the arms are not a like-for-like control comparison. The paired setup can account for characteristics shared by the portions of a participant’s incision, but it does not by itself remove possible differences between the treated and control locations. The method for choosing which portion received the device is not reported in the registry record.

The study start is recorded as 2011-09 and primary completion as 2012-11; the overall status is completed. The primary outcome timeframe is 6 months. Its population is defined in the record as all eligible patients who did not exit the study prematurely, per protocol. The number meeting that definition and the number with complete endpoint observations are not reported in the registry record.

There are four listed secondary outcomes: subject and investigator satisfaction with aesthetic results, ease of use, comfort related to device application, wear and removal, and comparison of scar smoothness on treated and control sides. Together with the primary outcome, the record lists five outcome measures. Although the record describes the study’s purpose and design, details such as a formal protocol, allocation procedure, analysis plan, and sample-size justification are not reported in the registry record.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: Per protocol, all eligible patients who did not exit the study prematurely.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: After meeting all eligibility criteria, 12 patients were enrolled.

6. Primary Endpoint

The registry lists the primary outcome as Visual Analogue Scale (VAS), measured over 6 months.

The primary endpoint is the Visual Analogue Scale (VAS) Scar Score at 6 months. It is intended to quantify the appearance or quality of a scar using a line that represents a continuum from normal skin, scored as 0, to a poor scar, scored as 10. An assessor marks the line to represent the scar’s appearance, and the position of the mark is translated into a score to one decimal place. The registry describes this outcome as being scaled by an independent panel.

A visual scale is used to turn an assessment of appearance into a numeric measure that can be summarized and compared. In general, a continuous score can describe gradations rather than only placing scars into categories. The registry identifies the reported summary as a mean with standard error, which would describe the average score and the precision of that estimated mean. It does not report the actual mean, standard error, participant count for the endpoint, or a treated-versus-control effect estimate.

The score’s direction matters for interpretation: lower values are nearer the scale’s normal-skin anchor, while higher values are nearer its poor-scar anchor. That direction is part of the scale definition, not evidence of a study result. The endpoint description does not provide a clinically meaningful threshold for interpreting a score difference, and no such threshold is reported in the registry record. The six-month timing identifies when the primary outcome was intended to be assessed; it does not establish that all enrolled participants posted an assessment at that time.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

What does a mean with standard error describe?

The primary endpoint is continuous, and the registry says it is summarized as a mean with standard error. In general, a mean describes the average of observed scores. A standard error describes the uncertainty in the estimated mean due to sampling variability; it is not the same as the spread of individual scores. A confidence interval, in general, uses an estimate and its uncertainty to express a range of values compatible with the data under the chosen method. No confidence interval is reported in the registry record, and no mean or standard error is reported for the primary endpoint.

The scale is anchored at 0 for normal skin and 10 for a poor scar. Its scores therefore have an ordered direction, but the record does not provide an interpretation threshold for deciding what size of difference would be important. A statistical summary and a clinical interpretation answer different questions: a numerical average describes the observed scores, while an importance threshold would help put a difference in context. The latter is not reported in the registry record.

How does the within-participant setup affect comparison?

In general, a paired or within-participant design compares two related observations from the same person. Because the observations share participant-level characteristics, an analysis can account for that relationship rather than treating the observations as independent. The study description says that one half of the incision received the device and the other half was managed according to standard care, with each participant serving as his or her own control. However, the statistical method used for this structure is not reported in the registry record. It would not be appropriate to assume that a paired test, a particular model, or any specific adjustment was used.

The registry identifies allocation as NA and states that the comparison is not randomized. In general, random allocation can reduce systematic differences in treatment assignment, while a nonrandom assignment process can leave room for selection effects. In this study, the treated and control portions may also differ in location or other local characteristics. The method for assigning the device to a portion and any method for addressing such differences are not reported in the registry record. The record’s caution that the arms are not a like-for-like control comparison is important when interpreting the setup.

What can be learned from missing result and analysis details?

The record lists five outcome measures and zero analyses. It describes the primary endpoint and several secondary outcomes, but does not report endpoint estimates, inferential tests, or confidence intervals. In general, an effect estimate describes the size and direction of a comparison, while an interval conveys its precision. A p-value, when used, addresses compatibility of the data with a specified statistical model and null hypothesis; it does not measure the size or practical importance of an effect. None of these numerical results for the primary comparison is reported in the registry record.

The record’s sample-size assumptions describe a planning illustration based on an observed effect, with a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation. The intended effect is described as a stated fraction of the observed effect. These are assumptions for a planning illustration, not a report of the trial’s original design process. The record does not give the trial’s own sample-size justification or a planned target derived from such a justification. No numerical planning results are reported in the registry record, so no participant requirement can be stated.

In general, power is the probability that a study will detect a specified effect under stated assumptions if that effect is present. A sample-size calculation based on an observed effect is a planning illustration, not observed power and not evidence that the study had a particular probability of detecting an effect. The observed effect itself can be uncertain, especially when based on a small study. The registry record does not report an inferential result from which to assess that effect or its uncertainty.

For a continuous outcome, the variance and the chosen model affect the precision of an estimate. General statistical methods may also need to account for correlation between measurements from the same participant. Where data are more variable than a model assumes, or where outcomes are correlated, standard errors and tests can be miscalibrated if the method does not accommodate those features. These are general considerations; the registry record does not report a model, variance assumptions, or a method for accounting for within-participant correlation. A claim about the specific adequacy of the analysis cannot be made from the registered information.

Counts of adverse events are descriptive in this record. In general, counts and denominators help indicate how many observations were recorded among those at risk, but they do not by themselves establish a causal relationship to an intervention. The registry record does not provide event descriptions or an analysis comparing safety outcomes. Because both sides belong to the same participants, the counts also do not represent independent participant groups.

10. Confidence Intervals for Each Arm

No two-arm comparison is shown for this trial, but each arm's mean can be given with a t-based 95% confidence interval computed from the posted mean, spread and number of participants.

R code and output

arm <- c("Treated Side", "Control Side")
n   <- c(10, 10)
m   <- c(3.78, 5.58)
sp  <- c(0.35, 0.39)
sd  <- sp * sqrt(n)      # standard errors converted to SDs
for (i in seq_along(n)) {
  se <- sd[i] / sqrt(n[i]); h <- qt(0.975, n[i] - 1) * se
  cat(sprintf("CARM|%s|%d|%.3f|%.3f|%.3f|%.3f\n", arm[i], n[i], m[i], sd[i], m[i] - h, m[i] + h))
}

CARM  Treated Side  10  3.780  1.107  2.988  4.572
CARM  Control Side  10  5.580  1.233  4.698  6.462

11. Multiplicity, Missing Data and Analysis Populations

The registry lists five outcome measures: the VAS Scar Score as the primary outcome and four secondary outcomes concerning aesthetic satisfaction, ease of use, comfort with device application, wear and removal, and scar smoothness on treated and control sides. Assessing several outcomes can raise a multiplicity issue: in general, the more statistical tests conducted, the greater the chance of at least one apparently notable result occurring by chance when all null hypotheses are true. Statistical plans may address this through a hierarchy of outcomes or adjustment methods. Whether any such approach was planned or used is not reported in the registry record.

The record lists zero analyses. It does not give results for the primary outcome or the secondary outcomes, nor does it report whether formal tests were performed. The registry record does not report a multiplicity adjustment, a hierarchy for interpreting secondary outcomes, or whether those outcomes were intended as descriptive. As a result, no claim about the handling of multiple comparisons can be made.

The primary outcome population is described as all eligible patients who did not exit the study prematurely, per protocol. The record does not report how many participants met that description, how many had a six-month score, or the reasons for any early exits or missing observations. Missing-data procedures, including any imputation or sensitivity analysis, are not reported in the registry record.

The distinction between enrollment and analysis population is important. Enrollment is 12, while the number contributing to each endpoint is not stated. Without endpoint denominators and information about missingness, the completeness and representativeness of the outcome data cannot be assessed. The registry record also does not describe an intention-to-treat analysis population or any analysis population beyond the per-protocol description for the primary outcome.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

Most frequent non-serious adverse event terms

The registry records zero serious adverse events among 12 at risk on the treated side and zero among 12 at risk on the control side. These are side-specific entries for a study in which each participant contributed both a treated and a control portion of an incision. They should not be read as counts from two independent participant groups. The record does not describe the serious-event definitions or provide further event-level detail.

Other adverse events are recorded for 4 on the treated side and 3 on the control side, with 12 at risk on each side. The terms, severity, timing, and relatedness of these events are not reported in the registry record. The entries therefore describe counts, not whether events were caused by the device or whether the sides differed in risk. Death entries are not reported in the registry record; the blank values should not be read as a reported count of zero.

In general, safety counts need context, including event definitions, observation duration, severity, and how events were attributed and collected. The registry record identifies the primary outcome timeframe as 6 months but does not give additional safety follow-up details. The posted figures are therefore limited to the recorded counts and denominators; they do not establish a broader safety profile.

13. What the Result Does, and Does Not, Mean

The study addresses a practical statistical question: whether scar appearance scores differ between a portion of a revised incision treated with the embrace device and a portion receiving the investigator’s standard of care. The design is within participant, and the primary measure is a six-month VAS Scar Score assessed by an independent panel. Those details clarify what the comparison was intended to examine.

The registry record does not report the actual primary scores or a comparison estimate. It therefore cannot establish the size or direction of a difference, or how precisely a difference was estimated. It also does not report a test result or confidence interval. The fact that the study is marked completed and has enrollment of 12 does not fill in these missing outcome results. Nor does the absence of a reported analysis demonstrate that no effect existed.

The design has features that matter for interpretation. Each participant served as his or her own control, but the registry identifies allocation as not randomized and cautions that the arms are not a like-for-like control comparison. The assignment procedure and the handling of possible differences between incision portions are not reported in the registry record. An independent panel is named as the assessor, but whether the panel was masked to treatment is not stated; masking is listed as none.

The adverse-event entries show zero serious adverse events recorded on either side, and other adverse events recorded for 4 on the treated side and 3 on the control side. The record does not identify those other events or report deaths. These counts are not a causal comparison and should be interpreted within the limits of the reported details.

In short, the record describes a small, single-group study with a split-incision comparison and a defined scar-rating scale. It does not provide the results required to judge whether the observed scar scores differed, how large any difference was, or how uncertain it was. The record also does not provide enough methodological detail to assess the analysis plan, missing-data handling, or the robustness of a treatment comparison.

14. Why This Trial Matters Statistically

This study illustrates how a clinical design can use each participant as a control while still requiring careful attention to the structure of the comparison. The treated and control observations are linked within a person, so a suitable analysis would need to account for that relationship. The registry describes the split-incision setup but does not report the analysis method. That gap prevents readers from checking whether the statistical approach matched the design.

It also highlights the distinction between an endpoint definition and an endpoint result. The VAS Scar Score is described with anchors and an assessment timeframe, and the record states that an independent panel used the scale. Yet the numerical outcome and its uncertainty are not reported. A clearly defined measure is necessary for interpretation, but without estimates and uncertainty it is not possible to quantify the comparison.

The record’s nonrandomized allocation and its explicit warning that the arms are not a like-for-like control comparison demonstrate why the design label matters. A within-participant setup can reduce some sources of between-person variability in general, but it does not automatically make the compared incision portions exchangeable. Allocation procedures, assessment masking, and methods for addressing local differences affect how confidently a contrast can be interpreted; those details are not reported in the registry record.

Finally, the distinction between planning and evidence matters. A sample-size illustration based on an observed effect is not a prospective justification for the study and is not observed power. The registry record does not report its own sample-size justification, analysis results, or missing-data procedures. The case therefore shows why estimates, denominators, analysis methods, and uncertainty are all important complements to a registered study design.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The enrollment is 12, and the record does not report the number of participants who contributed to the primary outcome. The per-protocol population is defined as eligible patients who did not exit prematurely, but the number in that population and the completeness of six-month assessments are not reported. This limits assessment of how much information underlies the intended endpoint.

The comparison is not randomized. Although each participant served as his or her own control, the record does not describe how the treated and control portions were selected. The sides or incision locations may not be comparable in all respects, and the record does not describe methods for addressing such differences. It also lists masking as none and does not specify whether the independent panel knew which portion received the device.

Primary and secondary outcome results are not reported in the registry record, despite the record listing five outcome measures and zero analyses. There is no reported estimate, confidence interval, or test result for the primary comparison. The record also does not describe the statistical method, multiplicity approach, missing-data handling, or a trial-specific sample-size justification. These omissions prevent assessment of the analysis and of the precision of any effect estimate.

For safety, the record gives side-specific counts but not descriptions of the other adverse events, severity, relatedness, or additional follow-up details. Death values are not reported. The available safety entries cannot support a detailed comparison or a conclusion about causation.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: Investigation of a Novel Silicone Dressing to Maximize the Outcomes of Scar Revision Procedures (IMPROVE) — NCT01430130.
• Registry record last updated 2014-11-28; status last verified 2014-11.
• Results first posted 2014-11-28.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

IMPROVE is a completed, single-group device study with enrollment of 12. The registry describes the embrace device being applied to half of a revised incision, while the other half received the investigator’s standard of care; each participant served as his or her own control. Allocation is listed as NA, and the record notes that the comparison is not randomized.

The primary outcome is the VAS Scar Score at 6 months, assessed by an independent panel and summarized as a mean with standard error. The scale runs from 0 for normal skin to 10 for a poor scar. The registry lists four secondary outcomes and five outcome measures overall, but zero analyses. Primary and secondary numerical results are not reported in the registry record.

Serious adverse events are recorded as zero on both sides, with 12 at risk per side. Other adverse events are recorded for 4 on the treated side and 3 on the control side, also with 12 at risk per side. Event details and deaths are not reported in the registry record. The analysis method, missing-data handling, and trial-specific sample-size justification are also not reported.